Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) —…
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) —…
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) —…
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete…
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete…
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to…
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to…
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at…
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at…
Merger with Notable expected to close in late September or October, subject to VBL’s S-4…
Merger with Notable expected to close in late September or October, subject to VBL’s S-4…
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot…
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot…